ストックスクリーナーアプリを入手
1.535
1.28%
0.015
前日終値:
$1.52
開ける：
$1.53
24時間の取引高:
400.86K
Relative Volume:
0.45
時価総額：
$187.17M
収益：
$34.16M
当期純損益:
$-50.62M
株価収益率:
-3.0217
EPS:
-0.508
ネットキャッシュフロー:
$703.00K
1週間 パフォーマンス:
-1.95%
1か月 パフォーマンス:
-18.55%
6か月 パフォーマンス:
-60.32%
1年 パフォーマンス:
-66.09%
1日の値動き範囲:
$1.48
$1.54
1週間の範囲:
$1.35
$1.62
52週間の値動き範囲:
$1.35
$4.96
Omniab Inc Stock (OABI) Company Profile
OABI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OABI
Omniab Inc
|
1.54 | 187.17M | 34.16M | -50.62M | 703.00K | -0.508 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.52 | 111.66B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.55 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
557.00 | 38.04B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
283.85 | 36.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.79 | 25.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Omniab Inc Stock (OABI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-11-29 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-04-21 | 開始されました | The Benchmark Company | Buy |
| 2023-04-13 | 開始されました | Craig Hallum | Buy |
| 2023-02-22 | 開始されました | Cowen | Outperform |
| 2023-02-13 | 開始されました | H.C. Wainwright | Buy |
| 2022-12-20 | 開始されました | Truist | Buy |
| 2022-12-16 | 開始されました | Credit Suisse | Outperform |
| 2022-11-29 | 開始されました | SVB Leerink | Outperform |
| 2022-11-28 | 開始されました | Stifel | Buy |
すべてを表示
Omniab Inc (OABI) 最新ニュース
Director’s Bold Move: A Major Investment in OmniAb Stock - TipRanks
Director Makes Bold Move with Major OmniAb Stock Purchase - TipRanks
Insider Buying: John Higgins Acquires 65,000 Shares of OmniAb In - GuruFocus
OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration® Platform at the 21st Annual PEGS Boston Summit - marketscreener.com
Hsbc Holdings PLC Makes New Investment in OmniAb, Inc. (NASDAQ:OABI) - Defense World
OmniAb’s (OABI) “Buy” Rating Reaffirmed at Benchmark - Defense World
OmniAb: Too Much Risk, Not Enough Reward (NASDAQ:OABI) - Seeking Alpha
OmniAb, Inc. (NASDAQ:OABI) Q1 2025 Earnings Call Transcript - MSN
OmniAb : May 2025 Corporate Overview - marketscreener.com
Earnings Release: Here's Why Analysts Cut Their OmniAb, Inc. (NASDAQ:OABI) Price Target To US$7.88 - simplywall.st
Dimensional Fund Advisors LP Increases Position in OmniAb, Inc. (NASDAQ:OABI) - Defense World
RBC Capital Remains a Buy on OmniAb (OABI) - The Globe and Mail
OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates - MSN
OmniAb’s Earnings Call: Growth Amid Challenges - TipRanks
OmniAb Introduces the xPloration® Partner Access Program - BioSpace
OmniAb Q1 2025 slides: Revenue growth and pipeline expansion amid cost controls By Investing.com - Investing.com South Africa
OmniAb Introduces the xPloration(R) Partner Access Program - marketscreener.com
Is OmniAb, Inc. (OABI) the Low Risk High Reward Stock Set to Triple by 2030? - Yahoo Finance
OmniAb Reports Steady Growth in Q1 2025 - TipRanks
OmniAb, Inc. (NASDAQ:OABI) Shares Acquired by Barclays PLC - Defense World
OmniAb Inc (OABI) Q1 2025 Earnings Call Highlights: Revenue Growth and Strategic Partnerships ... By GuruFocus - Investing.com Canada
Wells Fargo & Company MN Purchases 12,278 Shares of OmniAb, Inc. (NASDAQ:OABI) - Defense World
Earnings call transcript: OmniAb’s Q1 2025 shows revenue growth and cost control - Investing.com
10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey
OmniAb Q1 2025 slides: Revenue growth and pipeline expansion amid cost controls - Investing.com
OmniAb Inc reports results for the quarter ended March 31Earnings Summary - TradingView
OmniAb Reports First Quarter 2025 Financial Results and Business Highlights - Business Wire
OmniAb to Participate in Two Investor Conferences in November - marketscreener.com
Ratio Revelations: OmniAb Inc (OABI)’s Financial Metrics in the Spotlight - DWinneX
Veraxa and OmniAb to develop bispecific ADC tumour programme - Yahoo Finance
OmniAb, Veraxa Biotech Partner on Solid Tumor Drug Discovery Program - marketscreener.com
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program - The Manila Times
VERAXA Biotech AG and OmniAb, Inc. Announce Co-Discovery Alliance for Novel Bispecific Antibody Drug Conjugate Program Targeting Solid Tumors - Nasdaq
VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program - GlobeNewswire Inc.
VERAXA Biotech Enters Co-Discovery Alliance with OmniAb - Contract Pharma
OmniAb Inc [OABI] Records 200-Day SMA of $3.6405 - knoxdaily.com
A stock that deserves closer examination: OmniAb Inc (OABI) - uspostnews.com
OmniAb to Participate in Five Upcoming Investor Conferences - marketscreener.com
OmniAb Inc (OABI) Stock: Navigating Drops and Gains - investchronicle.com
Legal & General Group Plc Decreases Stock Holdings in OmniAb, Inc. (NASDAQ:OABI) - Defense World
OmniAb Inc (OABI) can make a big difference with a little luck - Sete News
Ratio Examination: OmniAb Inc (OABI)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
RBC Capital Mkts initates OmniAb Inc (OABI) stock to an Outperform - knoxdaily.com
Ratios Reveal: Breaking Down OmniAb Inc (OABI)’s Financial Health - DWinneX
OmniAb Inc (OABI) deserves closer scrutiny - uspostnews.com
Companies Like OmniAb (NASDAQ:OABI) Are In A Position To Invest In Growth - Yahoo Finance
OmniAb, Inc. (NASDAQ:OABI) Shares Purchased by Geode Capital Management LLC - Defense World
OmniAb expands board with two new directors By Investing.com - Investing.com South Africa
OmniAb Appoints New Directors to Board - TipRanks
OmniAb adds two new directors to its board - Investing.com Australia
OmniAb adds two new directors to its board By Investing.com - Investing.com India
Omniab Inc (OABI) 財務データ
収益
当期純利益
現金流量
EPS
Omniab Inc (OABI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| HIGGINS JOHN L | Director |
May 12 '25 |
Buy |
1.44 |
65,000 |
93,600 |
2,831,887 |
| FOEHR MATTHEW W | President and CEO |
Apr 07 '25 |
Option Exercise |
0.00 |
36,458 |
0 |
3,815,618 |
| FOEHR MATTHEW W | President and CEO |
Apr 07 '25 |
Sale |
2.00 |
19,382 |
38,764 |
3,796,236 |
| Berkman Charles S | Chief Legal Officer |
Apr 07 '25 |
Option Exercise |
0.00 |
13,542 |
0 |
370,418 |
| Berkman Charles S | Chief Legal Officer |
Apr 07 '25 |
Sale |
2.00 |
7,206 |
14,412 |
363,212 |
| GUSTAFSON KURT A | Executive VP, Finance and CFO |
Apr 07 '25 |
Option Exercise |
0.00 |
13,542 |
0 |
231,034 |
| GUSTAFSON KURT A | Executive VP, Finance and CFO |
Apr 07 '25 |
Sale |
2.00 |
7,206 |
14,412 |
223,828 |
1.68%
大文字化:
|
ボリューム (24 時間):